- Home
- CING vs BOLD Comparison
CING vs BOLD Comparison
Compare CING & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CING | BOLD |
|---|---|---|
| Founded | 2012 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.0M | 26.2M |
| IPO Year | 2021 | 2024 |
Fundamental Metrics
Financial Performance| Metric | CING | BOLD |
|---|---|---|
| Price | $3.92 | $1.14 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $31.33 | $4.00 |
| AVG Volume (30 Days) | 130.3K | ★ 173.3K |
| Earning Date | 11-13-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.20 | $1.00 |
| 52 Week High | $6.01 | $3.54 |
Technical Indicators
Market Signals| Indicator | CING | BOLD |
|---|---|---|
| Relative Strength Index (RSI) | 55.60 | 43.21 |
| Support Level | $3.80 | $1.00 |
| Resistance Level | $4.02 | $1.19 |
| Average True Range (ATR) | 0.18 | 0.07 |
| MACD | 0.06 | 0.00 |
| Stochastic Oscillator | 82.35 | 59.09 |
Price Performance
Historical ComparisonAbout CING Cingulate Inc.
Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic area to use PTR technology to develop future product candidates.
About BOLD Boundless Bio Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.